-
-
-
-
-
-
-
Syros Pharmaceuticals (SYRS) Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
-
-
-
-
-
-
-
Syros Pharmaceuticals (SYRS) Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in A
-
-
-
-
-
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

